Building Competency in Diabetes Education THE ESSENTIALS

BASAL-BOLUS INSULIN THERAPY | 12-110

79. Hamann S, Matthaei C, Rosak L, Silvestre for the HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003;26:173-44. 80. American Diabetes Association. Medical Management of Type 1 Diabetes, 6th ed. Alexandria, VA: American Diabetes Association, 2012. 81. Ashwell S, Gebbie J, Home P. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med 2006;23:879-86. 82. Rosenstock J, Park G, Zimmerman J; U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care. 2000;23:1137-42. 83. Rosenstock J, Schwarts L, Clark C, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2000;24:631-6. 84. NICE: National Institute for Health and Care Excellence. Type 1 diabetes mellitus in adults: High-strength insulin glargine 300 units/ml (Toujeo). October 13, 2015. Available at: swww.nice.org.uk/guidance/esnm62. 85. Novo Nordisk Canada Inc. Levemir® product monograph. November 9, 2017. Mississauga, ON, Canada. 86. Novo Nordisk Canada Inc. Tresiba product monograph. July 17, 2018. Missisauga, ON, Canada. 87. NICE: National Institute for Health and Care Excellence. Type 1 diabetes: Insulin degludec. September 10, 2013. Available at: www.nice.org.uk/guidance/esnm24. 88. Lipscombe L, Booth G, Butalia S, et al. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada: Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes 2018;42(Suppl 1):S88-S103. 89. Song C, Booth GL,Perkins BA, et al . Impact of government-funded insulin pump programs on insulin pump use in Canada: a cross-sectional study using the National Diabetes Repository. BMJ Open Diab Res Care 2021;9:e002371. doi:10.1136/bmjdrc-2021-002371 90. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in clients with type 1 diabetes: Meta- analysis of randomised controlled trials. Br Med J 2002;324:705-8. 91. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593-8. 92. Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31(Suppl 2):S140-S145.